Trump Targets Tablets

While Donald Trump has paused tariffs for now, signals suggest the pharma sector may not be spared if they return. With Indian pharma companies having nearly ₹1 lakh crore exposure to the U.S. market, investors could feel the heat. Mandar Wagh explains the resilience of the Indian pharmaceutical industry, how the U.S. drug shortage is becoming India’s advantage, why the sector might still come under pressure, and which companies could be affected or benefit as India stands to gain more than it loses amidst the ongoing U.S.-China trade tensions